• 1. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 2. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 5. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873

Research Brief on 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- (CAS: 2910-79-4): Recent Advances and Applications

The compound 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- (CAS: 2910-79-4) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This chalcone derivative, characterized by its α,β-unsaturated ketone moiety, exhibits a range of biological activities, including anti-inflammatory, anticancer, and antimicrobial properties. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and exploring its therapeutic potential in various disease models.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the anticancer activity of 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- against a panel of cancer cell lines. The compound demonstrated potent inhibitory effects on the proliferation of breast cancer (MCF-7) and colon cancer (HCT-116) cells, with IC50 values in the low micromolar range. Mechanistic studies revealed that the compound induces apoptosis via the mitochondrial pathway, accompanied by the upregulation of pro-apoptotic proteins such as Bax and caspase-3.

Another recent study, published in Bioorganic & Medicinal Chemistry Letters, explored the anti-inflammatory properties of this chalcone derivative. The researchers found that 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- significantly inhibits the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in lipopolysaccharide (LPS)-stimulated macrophages. The compound's activity was attributed to its ability to suppress the NF-κB signaling pathway, a key regulator of inflammatory responses.

From a synthetic chemistry perspective, advancements have been made in the efficient preparation of 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)-. A 2022 study in Tetrahedron Letters reported a novel one-pot synthesis method using a Claisen-Schmidt condensation reaction, which improved the yield and reduced the reaction time compared to traditional methods. This development is particularly relevant for scaling up production for preclinical and clinical studies.

Despite these promising findings, challenges remain in the development of 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- as a therapeutic agent. Issues such as poor solubility and potential off-target effects need to be addressed through structural modifications and formulation strategies. Ongoing research is focusing on the design of analogs with improved pharmacokinetic properties while retaining the compound's biological activity.

In conclusion, 2-Propen-1-one, 1-(4-bromophenyl)-3-(2-thienyl)- (CAS: 2910-79-4) represents a promising scaffold for the development of novel therapeutic agents. Its diverse biological activities and recent advancements in synthesis and mechanistic understanding highlight its potential in drug discovery. Future research should focus on optimizing its drug-like properties and evaluating its efficacy in in vivo models to further advance its translational potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)